Athena Countouriotis, Avenzo Therapeutics CEO (BioMarin)
November 18, 2024 07:00 AM ESTUpdated 08:25 AM
Startups
Deals
China

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

Kyle LaHucik

Senior Reporter

San Diego biotech Aven­zo Ther­a­peu­tics has in-li­censed an­oth­er as­set, this time se­cur­ing the glob­al ex-Chi­na rights to a bis­pe­cif­ic in the bustling an­ti­body-drug con­ju­gate space …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Cy­bin says its psy­che­del­ic drug can sus­tain re­mis­sion in de­pres­sion pa­tients

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times